331. 特発性多中心性キャッスルマン病 Idiopathic multicentric castleman disease Clinical trials / Disease details

臨床試験数 : 33 / 薬物数 : 41 - (DrugBank : 21) / 標的遺伝子数 : 22 - 標的パスウェイ数 : 123

6 trials found

diseases per page:

Showing 1 to 6 of 6 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	ChiCTR2100048364	2021-09-01	2021-07-06	A single-arm, prospective, and multicenter study of rituximabcombined with lenalidomide in Castleman ...	A single-arm, prospective, and multicenter study of rituximabcombined with lenalidomide in Castleman ...	Castleman disease	Treatment group:Rituximab+lenalidomide;	Department of Hematology, Jiangsu Provincial People's Hospital	NULL	Pending	14	90	Both	Treatment group:20;	Phase 4	China
2	NCT04585893 (ClinicalTrials.gov)	June 22, 2021	10/9/2020	Safety and Efficacy of Rituximab for Treatment of Multicentric Castleman Disease in Malawi	LCCC 1950 - Rituximabfor Multicentric Castleman Disease in Malawi, A Single-Arm Phase II Safety/Effi ...	Multicentric Castleman Disease	Drug: Rituximab;Drug: Etoposide	UNC Lineberger Comprehensive Cancer Center	Fogarty International Center of the National Institute of Health	Recruiting	18 Years	N/A	All	27	Phase 2	Malawi
3	NCT03864419 (ClinicalTrials.gov)	October 24, 2019	1/3/2019	RituximabHyaluronidase in Combination With Chemotherapy in Treating Aggressive B-cell Lymphoma in Ug ...	A Phase I Study of Subcutaneous RituximabHyaluronidase Combined With Local Standard-of-Care Chemothe ...	Burkitt Lymphoma;KSHV-associated Multicentric Castleman Disease;Diffuse Large B-Cell Lymphoma	Biological: Rituximab and Hyaluronidase Human;Drug: Cyclophosphamide;Drug: Vincristine;Drug: Methotre ...	Fred Hutchinson Cancer Center	NULL	Recruiting	2 Years	N/A	All	40	Phase 1	Uganda;United States
4	NCT02228512 (ClinicalTrials.gov)	August 15, 2014	27/8/2014	Study of Pomalidomide Combined With Modified DA-EPOCH and Rituximab in KSHV-Associated Lymphomas	Phase I/II Study of Pomalidomide Combined With Modified DA-EPOCH and Rituximabin KSHV-Associated Lym ...	Large Cell Lymphoma Arising in KSHV-associated Multicentric Castleman Disease;Primary Effusion Lymph ...	Drug: Pomalidomide;Drug: Rituximab;Drug: Prednisone;Drug: Etoposide;Drug: Doxorubicin;Drug: Vincrist ...	National Cancer Institute (NCI)	NULL	Withdrawn	18 Years	99 Years	All	0	Phase 1/Phase 2	United States
5	NCT00092222 (ClinicalTrials.gov)	October 28, 2004	21/9/2004	Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Corr ...	Targeted Oncolytic Virotherapy and Natural History Study of KSHV-Associated Multicentric Castleman's ...	Lymphoproliferative Disorder;HHV-8;Malignancy;HIV	Drug: Etoposide;Drug: Interferon-alpha;Drug: Rituximab;Drug: Zidovudine;Drug: Liposomal Doxorubicin; ...	National Cancer Institute (NCI)	NULL	Active, not recruiting	18 Years	N/A	All	75	Phase 2	United States
6	NCT00127569 (ClinicalTrials.gov)	May 2003	4/8/2005	Rituximabin the Treatment of HIV Associated Multicentric Castleman Disease Dependent on Chemotherapy ...	Multicenter, Phase II Trial Assessing the Efficacy of Rituximabin HIV Infected Patients With Multice ...	HIV Infections;Giant Lymph Node Hyperplasia	Drug: Rituximab	French National Agency for Research on AIDS and Viral Hepatitis	Hoffmann-La Roche	Terminated	18 Years	N/A	Both	25	Phase 2	NULL

First Previous1Next Last